Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study finds a subset of quick COVID-19 healers and antibody 'sustainers'

One of the pressing questions about COVID-19 remains: How long does immunity last? One key indicator of immunity is the presence of virus-specific antibodies.

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

Scientists identify neutralizing human monoclonal antibodies against SARS-CoV-2

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.

3 Nov 2020

Microneedle patch for rapid, blood-free malaria testing

Testing for malaria could become as simple as putting on a bandage.

2 Nov 2020

Study identifies new cause of COVID-19 blood clots

Blood clots continue to wreak havoc for patients with severe COVID-19 infection, and a new study explains what may spark them in up to half of patients.

2 Nov 2020

Two studies find age as a primary factor in melanoma treatment resistance

Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response.

2 Nov 2020

Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development

Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, announce the extension of a strategic collaboration to deliver industry-proven, innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.

From Thermo Fisher Scientific Inc. 2 Nov 2020

Study reveals seven “forms of disease” in COVID-19

In a study recently published in the top journal "Allergy", a team of MedUni Vienna scientists led by immunologist Winfried F. Pickl and allergologist Rudolf Valenta (both from the Center for Pathophysiology, Infectiology and Immunology) showed that there are seven "forms of disease" in COVID-19.

2 Nov 2020

Exposure to environmental immunotoxicants may worsen outcome of SARS-CoV-2 infection

A team of researchers recently carried out a study in Denmark in which they determined the plasma PFAS concentrations in individuals with a confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

2 Nov 2020

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Researchers tested 5-amino levulinic acid in vitro in human-derived cells and found it prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Because it is safe and ubiquitous in plants and animals, it could be a potential drug against SARS-CoV-2.

1 Nov 2020

UIC enrolls people into phase 3 monoclonal antibody clinical trial

Researchers at the University of Illinois Chicago are now enrolling people into a phase 3 clinical trial that will test if a monoclonal antibody treatment -- administered as a series of four shots -- will help protect uninfected individuals from acquiring or getting sick from COVID-19 after someone in the household tests positive for COVID-19.

30 Oct 2020

Children with multiple islet autoantibodies are more likely to progress to type 1 diabetes

Children with multiple islet autoantibodies - biological markers of autoimmunity -- are more likely to progress to symptomatic type 1 diabetes (T1D) than those who remain positive for a single autoantibody.

30 Oct 2020

Novel approach can help measure antibodies against SARS-CoV-2

A new study lead by Helmholtz Zentrum München indicates a six-fold higher SARS-CoV-2 exposure rate among children in Bavaria, Germany, than reported cases.

30 Oct 2020

Seroprevalence and immune response to SARS-CoV-2 in Paris

François Anna et al. published this study in a recent medRxiv* preprint paper, where they present the results of assessing the serological response in the selected population. They tested for specific IgG response against the SARS CoV-2 Nucleoprotein and Spike protein and performed a pseudo-neutralization assay in sera of urban dwellers in Paris.

30 Oct 2020

Booster dose enhances immunogenicity of ChAdOx1 SARS-CoV-2 vaccine in aged mice

Now, a new study published on the pre-print server bioRxiv* shows that a single dose of the vaccine has induced cellular and humoral immunity in aged or older mice. A second dosage was needed to enhance the vaccine's immune response, showing that a prime-boost strategy may be an essential step to boost immunogenicity in the elderly.

30 Oct 2020

COVID-19 study: Researchers recruit frontline workers to identify asymptomatic individuals

Fifteen hundred frontline workers are being recruited for a yearlong study to find what percentage are positive for the virus that causes COVID-19, what percentage become positive and whether the antibodies they produce protect them from reinfection.

30 Oct 2020

SARS-CoV-2 load varies widely in the community and over time

A new study published on the preprint server medRxiv* in October 2020 reports that there are large differences in the viral load in different communities. Moreover, the authors say that the cycle threshold values required to obtain a positive result for viral RNA by polymerase chain reaction may provide an early warning of an outbreak.

29 Oct 2020

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020

New method could help increase effectiveness of vaccines against coronavirus

A University at Buffalo-led research team has discovered a technique that could help increase the effectiveness of vaccines against the novel coronavirus, the virus that causes COVID-19.

29 Oct 2020

Majority of people infected with mild-to-moderate COVID 19 mount robust antibody response

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

29 Oct 2020